For US Healthcare Professionals

For US Healthcare Professionals

CURRENT TREATMENTS HAVE BEEN REVOLUTIONARY. BUT THERE'S EVEN MORE TO DISCOVER3-6

VEGF may not be the only driver of disease, yet it remains the only pathway treatments have successfully targeted to date3-6,21,22

Therapies currently in market suppress the overexpression of VEGF in order to slow angiogenesis and vascular leakage.3-6,21,22 This leaves opportunity to explore the connection between the inhibition of the Ang-Tie pathway and the upregulation of VEGF.1,2

EXPLORING NEW PATHWAYS IS ONLY THE START

When surveying retina specialists, durability proved to be the leading consideration24

In fact, data from the 2020 American Society of Retina Specialists (ASRS) Preferences and Trends (PAT) Survey show retina specialists considered “reduced treatment burden” as the greatest unmet need in patients with nAMD.*

A bar chart representing results from a 2020 survey of retina specialists.

*The survey question and categories were adopted by the ASRS and were not influenced and/or decided upon by Genentech.

Needle-shaped icon accompanying content about the connection between yearly injections and vision gains.

CLINICAL EXPECTATIONS

Vision outcomes reported in clinical trials are typically tied to the number of anti-VEGF monotherapy injections received per year. However, challenges in the real world can lead to challenges in patient adherence, which may have an effect on vision gains.25-27

Ang-Tie=angiopoietin/Tie; nAMD=neovascular age-related macular degeneration; VEGF=vascular endothelial growth factor.

    • Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661. 

      Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661. 

    • Fiedler U, et al. Nat Med. 2006;12:235-239. 

      Fiedler U, et al. Nat Med. 2006;12:235-239. 

    • MACUGEN [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016. 

      MACUGEN [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016. 

    • LUCENTIS [prescribing information]. South San Francisco, CA: Genentech, Inc; 2018. 

      LUCENTIS [prescribing information]. South San Francisco, CA: Genentech, Inc; 2018. 

    • BEOVU [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020. 

      BEOVU [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020. 

    • EYLEA [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.

      EYLEA [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.

    • Mulligan K, et al. JAMA Ophthalmol. 2020;138(1):40-47.

      Mulligan K, et al. JAMA Ophthalmol. 2020;138(1):40-47.

    • Baumal CR. Am J Manag Care. 2020;26(5 suppl):S103-S111.

      Baumal CR. Am J Manag Care. 2020;26(5 suppl):S103-S111.

    • Kim E, et al. Curr Diab Rep. 2019;19(68):1-10.

      Kim E, et al. Curr Diab Rep. 2019;19(68):1-10.

    • Romero-Aroca P. World J Diabetes. 2011;2(6):98-104.

      Romero-Aroca P. World J Diabetes. 2011;2(6):98-104.

    • Hakanpaa L, et al. Nat Commun. 2015;6:1-12.

      Hakanpaa L, et al. Nat Commun. 2015;6:1-12.

    • Augustin HG, et al. Nat Rev Mol Cell Biol. 2009;10:165-177.

      Augustin HG, et al. Nat Rev Mol Cell Biol. 2009;10:165-177.

    • Nambu H, et al. Gene Ther. 2004;11:865-873.

      Nambu H, et al. Gene Ther. 2004;11:865-873.

    • Mueller SB, et al. J Clin Invest. 2016;126(9):3188-3191.

      Mueller SB, et al. J Clin Invest. 2016;126(9):3188-3191.

    • Bolinger MT, et al. Int J Mol Sci. 2016;17:1-23.

      Bolinger MT, et al. Int J Mol Sci. 2016;17:1-23.

    • Bressler SB. Ophthalmology. 2009;116:S1-S7.

      Bressler SB. Ophthalmology. 2009;116:S1-S7.

    • Scott IU, et al. Diabetes and Ocular Disease: Past, Present, and Future Therapies. 2010. Oxford; New York: Oxford University Press in cooperation with the American Academy of Ophthalmology.

      Scott IU, et al. Diabetes and Ocular Disease: Past, Present, and Future Therapies. 2010. Oxford; New York: Oxford University Press in cooperation with the American Academy of Ophthalmology.

    • Clapp C, et al. Physiol Rev. 2009;89:1177-1215.

      Clapp C, et al. Physiol Rev. 2009;89:1177-1215.

    • Kienast Y, et al. Clin Cancer Res. 2013;19:6730-6740.

      Kienast Y, et al. Clin Cancer Res. 2013;19:6730-6740.

    • Klaassen I, et al. Prog Retin Eye Res. 2013;1-30.

      Klaassen I, et al. Prog Retin Eye Res. 2013;1-30.

    • Bhisitkul RB. Br J Ophthalmol. 2006;90:1542-1547.

      Bhisitkul RB. Br J Ophthalmol. 2006;90:1542-1547.

    • Shibuya M. Genes Cancer. 2011;2:1097-1105.

      Shibuya M. Genes Cancer. 2011;2:1097-1105.

    • Ciulla TA, et al. Ophthalmol Retina. 2020;4:19-30

      Ciulla TA, et al. Ophthalmol Retina. 2020;4:19-30

    • Hahn P, ed. ASRS 2020 Preferences and Trends Membership Survey. American Society of Retina Specialists; 2020.

      Hahn P, ed. ASRS 2020 Preferences and Trends Membership Survey. American Society of Retina Specialists; 2020.

    • Cohen SY, et al. Retina. 2013;33:474-481.

      Cohen SY, et al. Retina. 2013;33:474-481.

    • Holz FG, et al. Br J Ophthalmol. 2015;99:220-226.

      Holz FG, et al. Br J Ophthalmol. 2015;99:220-226.

    • Holekamp NM, et al. Am J Ophthalmol. 2018;191:83-91.

      Holekamp NM, et al. Am J Ophthalmol. 2018;191:83-91.